206. Fragile X syndrome Clinical trials / Disease details
Clinical trials : 104 / Drugs : 87 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01120626 (ClinicalTrials.gov) | September 2009 | 7/5/2010 | Randomized Controlled Study of Donepezil in Fragile X Syndrome | Augmentation of the Cholinergic System in Fragile X Syndrome: A Double-Blind Placebo-Controlled Randomized Study of Donepezil | Fragile X Syndrome | Drug: donepezil;Drug: sugar pill | Stanford University | National Institute of Mental Health (NIMH);Autism Speaks | Completed | 12 Years | 29 Years | All | 45 | Phase 2 | United States |